Resultados globales: 2 registros encontrados en 0.03 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
8 p, 412.5 KB Subgroup analysis in RAISE : a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression / Obermannová, R. (Masaryk Memorial Cancer Institute (Czech Republic)) ; Van Cutsem, E. (KU Leuven. University Hospitals Leuven (Belgium)) ; Yoshino, T. (National Cancer Center Hospital East (Japan)) ; Bodoky, G. (St László Hospital (Hungary)) ; Prausová, J. (Charles University. Onocology Clinic (Czech Republic)) ; Garcia-Carbonero, R. (Hospital Universitario Doce de Octubre) ; Ciuleanu, T. (Institutul Oncologic Ion Chiricuta and UMF (Romania)) ; Garcia Alfonso, P. (Hospital General Universitario Gregorio Maraňón) ; Portnoy, D. (The University of Tennessee. Health Science Center (USA)) ; Cohn, A. (Rocky Mountain Cancer Center (USA)) ; Yamazaki, K. (Shizouka Cancer Center (Japan)) ; Clingan, P. (Southern Medical Day Care Centre (Australia)) ; Lonardi, S. (Istituto Oncologico Veneto-IRCCS (Italy)) ; Kim, T. W. (University of Ulsan College of Medicine. Asan Medical Center (South Corea)) ; Yang, L. (Eli Lilly and Company (USA)) ; Nasroulah, F. (Eli Lilly and Company (República Argentina)) ; Tabernero Caturla, Josep (Institut d'Oncologia de la Vall Hebron (VHIO)) ; Universitat Autònoma de Barcelona
The RAISE phase III trial demonstrated ramucirumab + FOLFIRI improved survival compared with placebo + FOLFIRI for second-line metastatic colorectal carcinoma patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. [...]
2016 - 10.1093/annonc/mdw402
Annals of Oncology, Vol. 27, Issue 11 (November 2016) , p. 2082-2090  
2.
7 p, 199.8 KB CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab -paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer / Chiorean, E. G. (University of Washington. Department of Medicine) ; Von Hoff, D. D. (Translational Genomics Research Institute) ; Reni, M. (Ospedale San Raffaele. Servizio di Oncologia Medica) ; Arena, F. P. (NYU Langone Arena Oncology. Department of Oncology) ; Infante, J. R. (Sarah Cannon Research Institute) ; Bathini, V. G. (University of Massachusetts Medical School. Cancer Center of Excellence) ; Wood, T. E. (University of Alabama at Birmingham. Comprehensive Cancer Center) ; Mainwaring, P. N. (Centre for Haematology & Oncology (Brisbane, Austràlia)) ; Muldoon, R. T. (Genesis Cancer Center. Department of Oncology) ; Clingan, P. R. (Southern Medical Day Care Centre) ; Kunzmann, V. (Universitätsklinikum Würzburg. Medizinischen Klinik und Poliklinik II) ; Ramanathan, R. K. (Translational Genomics Research Institute) ; Tabernero Caturla, Josep (Hospital Universitari de la Vall d'Hebron) ; Goldstein, D. (Prince of Wales Hospital. Department of Oncology) ; McGovern, D. (Celgene Corporation) ; Lu, B. (Celgene Corporation) ; Ko, A. (Celgene Corporation) ; Universitat Autònoma de Barcelona
Any CA19-9 decline at week 8 and radiologic response by week 8 each predicted longer OS in both treatment arms. In the nab- P + Gem arm, the higher proportion of patients with week 8 CA19-9 decrease [82% (206/252); median OS 13. [...]
2016 - 10.1093/annonc/mdw006
Annals of oncology, Vol. 27, issue 4 (April 2016) , p. 654-660  

Vea también: autores con nombres similares
1 Clingan, P. R.
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.